Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – In an organic compound
Patent
1996-12-17
1999-09-28
Dees, Jose' G.
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
In an organic compound
424 169, 424 149, 424 153, 424 111, 534 10, A61K 5100, C07F 500
Patent
active
059583746
ABSTRACT:
Radionuclide-labeled chelating agent-ligand complexes that are useful in medical diagnosis or therapy are prepared by reacting a radionuclide, such as .sup.90 Y or .sup.111 In, with a polyfunctional chelating agent to form a radionuclide chelate that is electrically neutral; purifying the chelate by anion exchange chromatography; and reacting the purified chelate with a targeting molecule, such as a monoclonal antibody, to form the complex.
REFERENCES:
patent: 4885363 (1989-12-01), Tweedle et al.
patent: 5006643 (1991-04-01), Fazio et al.
patent: 5217704 (1993-06-01), Johnson et al.
patent: 5284644 (1994-02-01), Kruper, Jr. et al.
patent: 5435990 (1995-07-01), Cheng et al.
patent: 5514363 (1996-05-01), Shochat et al.
Moi, M.K., et al., "Copper chelates as probes of biological systems: Stable copper complexes with a macrocyclic bifunctional chelating agent" Anal. Biochem. (1985) 148:249-253.
Moi, M.K., et al., "The peptide way to macrocyclic bifunctional chelating agents: Synthesis of 2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecane-N,N',N",N'"-tetraacetic acid and study of its yttrium(III) complex" J. Am. Chem. Soc. (1988) 110:6266-6267.
Cox, J.P.L., et al., "Synthesis of C- and N-functionalised derivatives of 1,4,7-triazacyclononane-1,4,7-triyltriacetic acid (NOTA), 1,4,7,10-tetra-azacyclododecane-1,4,7,10-tetrayltetra-acetic acid (DOTA), and diethylenetriaminepenta-acetic acid (DPTA): Bifunctional complexing agents for the derivatisation of antibodies" J. Chem. Soc. Perkin Trans. 1 (1990) pp. 2567-2576.
Parker, D., "Tumour targeting with radiolabelled macrocycle-antibody conjugates" Chem. Soc. Rev. (1990) 19:271-291.
Meares, C.F., et al., "Macrocyclic chelates of radiometals for diagnosis and therapy" Brit. J. Cancer (1990) 10:21-26.
Gansow, O.A., "Newer approaches to the radiolabelling of monoclonal antibodies by use of metal chelates" Nucl. Med. Biol. (1991) 18:369-381.
Li, M., et al., "Synthesis, metal chelate stability studies, and enzyme digestion of a peptide-linked DOTA derivative and its corresponding radiolabeled immunoconjugates" Bioconjugate Chem. (1993) 4:275-283.
Deshpande, S.V., et al., "Yttrium-90-labeled monoclonal antibody for therapy: Labelling by a new macrocyclic bifunctional chelating agent" J. Nucl. Med., (1990) 31:473-479.
Kasprzyk, S.P., et al., "Kinetics of interaction of metal ions with two tetraaza tetraacetate macrocycles" Inorg. Chem. (1982) 21:3349-3352.
Kodama, M., et al., "Thermodynamic and kinetic studies of lanthanide complexes of 1,4,7,10,13-pentaazacyclopentadecane-N,N', N", N'", N""-pentaacetic acid and 1,4,7,10,13,16-hexaazacyclo octadecane-N,N',N",N'", N"", N'""-hexaacetic acid" Inorg. Chem. (1991) 30:1270-1273.
Wang, X., et al., "A kinetic investigation of lanthanide DOTA chelates. Stability and rates of formation and of dissociation of a macrocyclic gadolinium(III) polyaza polycarboxylic MRI contrast agent" Inorg. Chem. (1992) 31:1095-1099.
Fritzberg, A.R., et al., "Specific and stable labeling of antibodies with technetium-99m with a diamide dithiolate chelating agent" Proc. Natl. Acad. Sci. USA (1988) 85:4025-4029.
Franz, J., et al., "The production of .sup.99m Tc-labeled conjugated antibodies using a cyclam-based bifunctional chelating agent" Nucl. Med. Biol. (1987) 14:569-572.
Linder, K.E., et al., "Technetium labeling of monoclonal antibodies with functionalized BATOs. 1. TcCl(DMG).sub.3 PITC" Bioconjugate Chem. (1991) 2:160-170.
Schlom, J., et al., "Monoclonal antibody-based therapy of a human tumor xenograft with a .sup.177 Lutetium-labeled immunoconjugate" Cancer Res. (1991) 51:2889-2896.
Kosmas, C., et al., "Development of humoral immune responses against a macrocyclic chelating agent (DOTA) in cancer patients receiving radioimmunoconjugates for imaging and therapy", Cancer Res. (1992) 52:904-911.
Wessels, B.W., et al., "Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodies" Med. Phys. (1984) 11:638-645.
Fell, H.P., et al., "Chimeric L6 anti-tumor antibody", J. Biol. Chem. (1992) 267:15552-15558.
Penefsky, H.S., "A centrifuged-column procedure for the measurement of ligand binding by beef hears F.sup.1 " et al., Meth. Enzymol. (1979) 56:Part G: 527-530.
Meares, C.F., et al., "Conjugation of antibodies with bifunctional chelating agents: Isothiocyanate and bromoacetamide reagents, methods of analysis, and subsequent addition of metal ions" Anal. Biochem. (1984) 142:68-78.
DeNardo, S.J., et al., "Immunochemical aspects of monoclonal antibodies important for radiopharmaceutical development" Nucl. Med. Biol. (1986) 13:303-310.
Hellstrom, I., et al., "Monoclonal mouse antibodies raised against human lung carcinoma" (1986) Cancer Res. (1986) 46:3917-3923.
Encyclopedia of Chemical Technology, 4th vol. 14, 1995, pp. 737-741.
DeNardo Sally J.
Li Min
Meares Claude F.
Dees Jos,e G.
Hartley Michael G.
The Regents of the University of California
LandOfFree
Method for preparing radionuclide-labeled chelating agent-ligand does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for preparing radionuclide-labeled chelating agent-ligand, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for preparing radionuclide-labeled chelating agent-ligand will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-699935